Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair
Fanconi anemia (FA) is a cancer predisposition syndrome characterized by congenital abnormalities, bone marrow failure, and hypersensitivity to aldehydes and crosslinking agents. For FA patients, gene editing holds promise for therapeutic applications aimed at functionally restoring mutated genes in...
Main Authors: | Van De Vrugt, HJ, Harmsen, T, Riepsaame, J, Alexantya, G, Van Mil, SE, De Vries, Y, Bin Ali, R, Huijbers, IJ, Dorsman, JC, Wolthuis, RMF, Riele, H |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2019
|
Similar Items
-
CRISPR/Cas9 technology: from cells to mice to stem cell therapy
by: Te Riele, H, et al.
Published: (2016) -
Studies of the Fanconi anemia pathway
by: Liang, C
Published: (2016) -
CRISPR-Cas gene perturbation and editing in human induced pluripotent stem cells
by: van Essen, M, et al.
Published: (2021) -
The role of UHRF1 in Fanconi anemia pathway
by: Zhan, B
Published: (2013) -
A prototypical Fanconi anemia pathway in lower eukaryotes?
by: McHugh, P, et al.
Published: (2012)